SI-BONE, Inc. (NASDAQ:SIBN – Get Free Report) CFO Anshul Maheshwari sold 1,733 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $17.59, for a total value of $30,483.47. Following the sale, the chief financial officer now directly owns 148,738 shares in the company, valued at $2,616,301.42. The sale was disclosed in a filing with the SEC, which is available through this link.
Anshul Maheshwari also recently made the following trade(s):
- On Monday, October 2nd, Anshul Maheshwari sold 1,244 shares of SI-BONE stock. The stock was sold at an average price of $21.15, for a total value of $26,310.60.
SI-BONE Stock Up 2.9 %
Shares of SIBN traded up $0.50 during midday trading on Monday, reaching $18.04. 230,933 shares of the stock were exchanged, compared to its average volume of 355,422. SI-BONE, Inc. has a 52 week low of $11.14 and a 52 week high of $29.51. The company has a current ratio of 10.89, a quick ratio of 9.74 and a debt-to-equity ratio of 0.21. The company’s 50 day moving average is $18.93 and its two-hundred day moving average is $22.72. The company has a market capitalization of $730.64 million, a P/E ratio of -15.16 and a beta of 0.99.
Institutional Investors Weigh In On SI-BONE
Analyst Upgrades and Downgrades
SIBN has been the topic of several recent research reports. Cantor Fitzgerald decreased their price objective on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Needham & Company LLC decreased their price target on SI-BONE from $32.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. Truist Financial decreased their price target on SI-BONE from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday, August 8th. Finally, Morgan Stanley decreased their price target on SI-BONE from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Tuesday, November 7th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $27.17.
SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma.
- Five stocks we like better than SI-BONE
- EV Stocks and How to Profit from Them
- The most upgraded stocks in November have two things in common
- How to Invest and Trade Chinese Stocks
- Monday.com rocked earnings like it’s the weekend
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Plan to own one retailer? Make it this one
Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.